ResMed (NYSE: RMD) CFO sells 1,000 shares under Rule 10b5-1 plan

Rhea-AI Filing Summary

ResMed Inc.’s Chief Financial Officer Brett Sandercock reported a planned sale of company stock. On February 2, 2026, he sold 1,000 shares of ResMed common stock at $257.03 per share under a Rule 10b5-1 trading plan adopted on February 19, 2025.

After this transaction, Sandercock directly holds 85,495 ResMed shares. Rule 10b5-1 plans allow executives to pre-schedule trades, helping separate routine portfolio moves from day-to-day market or company news.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	02/02/2026		S(1)		1,000	D	$257.03	85,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

	/s/ Brett Sandercock, Chief Financial Officer	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) disclose in this Form 4?

ResMed disclosed that its Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock. The sale occurred on February 2, 2026, and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2025.

At what price did the ResMed (RMD) CFO sell his 1,000 shares?

The ResMed CFO sold 1,000 shares at a price of $257.03 per share. This transaction involved ResMed common stock and was reported as a sale coded “S” in the filing, reflecting a routine disposition rather than an acquisition of additional shares.

How many ResMed (RMD) shares does the CFO own after this transaction?

Following the reported sale, ResMed’s CFO Brett Sandercock beneficially owns 85,495 shares of ResMed common stock. These holdings are reported as directly owned, meaning they are not shown as held through an intermediate entity or indirect ownership structure in this filing.

What is a Rule 10b5-1 trading plan mentioned in the ResMed (RMD) filing?

A Rule 10b5-1 trading plan allows insiders to pre-schedule trades according to preset instructions. ResMed’s filing notes the CFO’s sale was conducted under such a plan adopted on February 19, 2025, helping separate the timing of trades from later, potentially material, information.

Who is the reporting person in this ResMed (RMD) Form 4 filing?

The reporting person is Brett Sandercock, Chief Financial Officer of ResMed Inc. The filing identifies him as an officer, not a director or 10% owner, and reports his direct ownership and the sale of 1,000 shares of ResMed common stock on February 2, 2026.

Is the ResMed (RMD) CFO’s share sale a direct or indirect transaction?

The sale is reported as a direct transaction, coded with ownership form “D” in the filing. This indicates the 1,000 ResMed common shares sold, and the remaining 85,495 shares, are held directly by CFO Brett Sandercock rather than through an entity or indirect structure.